Navigation Links
Pipeline for New Obesity Therapies is Focus of New Report

SCOTTSDALE, Ariz., Jan. 7 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published "Thought Leader Insight & Analysis: Obesity," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for obesity therapies.

By many measures, obesity in the Western World is reaching epidemic proportions. Unlike diabetes and cardiovascular disease, however, the medical justification for treating obesity is not directly tied to hard outcomes, and the pharmacoeconomics do not yet motivate third-party payers to broadly reimburse for pharmacotherapies.

Against this backdrop, seven internationally-recognized obesity experts comment on centrally acting, peripheral and non-systemic approaches to weight reduction, including:

-- Rimonabant, comparing next-generation CB-1 antagonists and inverse

agonists in terms of efficacy and propensity to cause depression and

other psychiatric disorders,

-- Other centrally acting agents, alone and in combination,

-- The pure peripheral drugs, using exenatide as the base for comparison

and positioning other GLP-1 agonists against its weaknesses,

-- Leptin, PYY, mitochondrial metabolism and other approaches to

"inefficient caloric consumption",

-- And non-systemic mechanisms, including follow up approaches after

orlistat, and novel approaches such as SGLT inhibition.

Key drugs discussed in this report include: Acomplia (rimonabant; Sanofi-Aventis), taranabant (MK-0364; Merck), CP-945598 (Pfizer), SLV 319 (BMS-646256; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), Contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byetta (exenatide; Amylin/Lilly), exenatide LAR (Lilly/Amylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside / Chinese Academy of Science); Substituted quinoxalines (Novo Nordisk/ Pfizer), PYY 3-36 (Nastech), CYT009-GhrQb (Cytos), Xenical / alli (orlistat; Roche / GSK), cetilistat (Alizyme/ Takeda), SGLT inhibitors.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
2. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
3. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. China Holdings, Inc. Announces Its 3rd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 150 MW in Biomass Energy Pipeline
6. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
7. Biotech Company Builder Papadopoulos Says Investment in Innovation Needed to Advance Drug Pipeline at Massachusetts Biotechnology Councils Ninth Annual MASS Opportunities Investment Conference
8. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
9. Clinical studies in the pipeline: the therapies of tomorrow in trials today
10. Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology: